Novo Nordisk successfully prices Euro medium term notes worth EUR 1.3bn

The proceeds will be used for general corporate purposes, including the refinancing of a bridge loan.

Photo: Jacob Gronholt-Pedersen/REUTERS / X04292

Novo Nordisk has successfully priced EUR 1.3bn (USD 1.6bn) notes, according to a press release published on Thursday.

The notes are issued in two tranches on June 4 2021. The first tranche, with an EUR 650m aggregate principal amount, matures on June 4 2024 with a coupon of 0 percent. The second tranche will have the same aggregate principal amount, matures on June 4 2028 and has a 0.125 percent coupon.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs